Bundgaard Christoffer, Jørgensen Martin, Mørk Arne
Discovery ADME, H. Lundbeck A/S, Copenhagen, Denmark.
J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):214-23. doi: 10.1016/j.vascn.2006.07.001. Epub 2006 Aug 4.
Integrated in vivo models applying intracerebral microdialysis in conjunction with automated serial blood sampling in conscious, freely moving rodents are an attractive approach for pharmacokinetic (PK) and simultaneous pharmacokinetic/pharmacodynamic (PK/PD) investigations of CNS active drugs within the same animal. In this work, the ability to obtain and correlate data in this manner was evaluated for the selective serotonin (5-HT) reuptake inhibitor (SSRI) escitalopram.
An instrumented rat model equipped with an intracerebral hippocampal microdialysis probe and indwelling arterial and venous catheters was applied in the studies. Concomitant with brain microdialysis, serial blood sampling was conducted by means of an automated blood sampling device. The feasibility of the rat model for simultaneous PK/PD investigations was examined by monitoring plasma and brain extracellular concentrations of escitalopram along with SSRI-associated pharmacological activity, monitored as changes in brain 5-HT levels and plasma corticosterone levels.
Combining intracerebral microdialysis and automated blood sampling did not cause any detectable physiological changes with respect to basal levels of plasma corticosterone or brain 5-HT levels. Furthermore, the PK of escitalopram in hippocampus following intravenous injection was not influenced by the presence of vascular catheters. Conversion of escitalopram dialysate concentrations into absolute extracellular levels by means of in vivo retrodialysis was verified by the no-net-flux method, which gave similar recovery estimates. The PK of escitalopram could be characterized simultaneously in plasma and the hippocampus of conscious, freely moving rats. Concomitantly, the modulatory and functional effects of escitalopram could be monitored as increases in brain 5-HT and plasma corticosterone levels following drug administration.
The applicability of intracerebral microdialysis combined with arterial blood sampling was demonstrated for simultaneous PK/PD investigations of escitalopram in individual rats under non-stressful conditions. Together, these temporal relationships provide multiple PK/PD information in individual animals, hence minimizing inter-animal variation using a reduced number of animals.
将脑内微透析与清醒、自由活动啮齿动物的自动连续采血相结合的体内综合模型,是在同一动物体内进行中枢神经系统活性药物药代动力学(PK)以及同步药代动力学/药效学(PK/PD)研究的一种有吸引力的方法。在本研究中,对选择性5-羟色胺(5-HT)再摄取抑制剂(SSRI)艾司西酞普兰以这种方式获取数据并进行关联的能力进行了评估。
在研究中使用了配备脑内海马微透析探针以及留置动脉和静脉导管的仪器化大鼠模型。在进行脑微透析的同时,通过自动采血装置进行连续采血。通过监测艾司西酞普兰的血浆和脑细胞外浓度以及与SSRI相关的药理活性(以脑5-HT水平和血浆皮质酮水平的变化作为监测指标),来检验该大鼠模型用于同步PK/PD研究的可行性。
将脑内微透析与自动采血相结合,并未导致血浆皮质酮或脑5-HT水平的基础值出现任何可检测到的生理变化。此外,静脉注射后艾司西酞普兰在海马中的药代动力学不受血管导管存在的影响。通过无净通量法验证了利用体内反透析将艾司西酞普兰透析液浓度转换为绝对细胞外水平的方法,该方法给出了相似的回收率估计值。艾司西酞普兰的药代动力学可以在清醒、自由活动大鼠的血浆和海马中同时进行表征。同时,给药后随着脑5-HT和血浆皮质酮水平的升高,可以监测到艾司西酞普兰的调节和功能作用。
脑内微透析与动脉采血相结合的方法在非应激条件下对个体大鼠进行艾司西酞普兰同步PK/PD研究的适用性得到了证实。这些时间关系共同为个体动物提供了多个PK/PD信息,从而使用较少数量的动物最大限度地减少了动物间的差异。